Low-dose Doxepin. I want to do a real deep dive on this one, because it's quietly become the most impactful thing in my recovery stack, and if it worked this well for me I’m sure at least one of you would experience the same. If you've ever been handed trazodone, Ambien, or told to just take some ZQuil, this is the conversation nobody had with you. What it actually is Doxepin is an old tricyclic antidepressant. At standard antidepressant doses (25–150 mg) it's a messy drug — it hits serotonergic, adrenergic, and cholinergic receptors all at once. That's the full tricyclic profile, and it's why most people think of it as heavy. But at ultra-low doses (3–6 mg), it becomes a completely different molecule. Those other receptors go quiet. What's left is a clean, selective H1 (histamine) antagonist — roughly seven times more potent at H1 than the classic over-the-counter antihistamine everyone reaches for. So you get the sleep-maintenance benefit of blocking histamine without the anticholinergic baggage that wrecks sleep architecture. Why it's different from everything else you've tried This is the part that matters. It is not a sedative and not a Z-drug. - It's not for sleep onset. The signal is on staying asleep — maintenance — not knocking you out faster. - It doesn't bulldoze your sleep architecture the way sedatives and Z-drugs do. You keep the deep, restorative stages instead of getting sedated into a shallow imitation of sleep. That last point is the whole game, and it's why it matters for body composition (more below). What the clinical data shows This isn't bro-science. A crossover RCT of 67 adults with primary insomnia (Roth et al., SLEEP 2007) tested doxepin 1, 3, and 6 mg against placebo: - −23 min wake after sleep onset (WASO) - +25–29 min total sleep time - Sleep efficiency 81% → 87% at 6 mg - Final third of the night: 80% → 89% efficiency That final-third number is the tell. It holds your sleep together through the back half of the night, which is exactly where most people fall apart.

Here's a closer look at how this works as well as the gateway of fat loss that takes place, synergistically working with GH. Key pieces to note: ANGPTL 3/8 works independently from the LDLR unlike statins and unlike PCSK9i's. The mechanism in which this occurs specifically is through Endothelial Lipase release. ANGPTL 3/8 Suppresses EL. When in a fed state, ANGPTL 3/8 is high. This suppresses EL and inhibits it from hydrolyzing phospholipids on HDL-c & LDL-c. When it's not suppressed, EL is activated and it processes VLDL remnants, therefore depleting the LDL-c precursor pool, ultimately reducing the amount of LDL-c. Again, this happens completely independently from the LDLR.

By this point we've all heard about Reta/Retatrutide. Safe to say by now it's also predominately known as a tool that simply helps with fat loss. Sometimes it doesn't even go beyond that for people to jump on board. There are some other really awesome mechanisms that are less spoken about when it comes to glucagon agonism, and that's the effect on lipid lowering via the ANGPTL 3/8 protein. Let's dive in: How is it actually lowering cholesterol? It's via the angiopoietin-like protein (ANGPTL 3/8). There are eight of these angiopoietin-like proteins (ANGPTL 1-8), and for lipid metabolism, three matter: - ANGPTL3: secreted by the liver, circulates systemically. It inhibits LPL in oxidative tissues (muscle, heart) and inhibits EL on the endothelium - ANGPTL4: secreted by adipose, liver, and heart. Inhibits LPL primarily in adipose during fasting. Inactivated by ANGPTL8 during feeding. - ANGPTL8: produced by liver and adipose. Acts as a molecular switch and pairs with ANGPTL4 to activate it forming (ANGPTL3/8). How ANGPTL 3/8 is regulated - Fed state (insulin is high). ANGPTL8 rises in liver & adipose. Liver ANGPTL8 binds with ANGPTL3 and creates the combo 3/8. This combination inhibits LPL in oxidative tissues (muscle, heart). Ultimately dietary fat is routed to adipose for storage - Fasted state (glucagon high) ANGPTL8 falls and ANGPTL4 suppresses LPL in adipose. ANGPTL3/8 also falls, freeing up LPL in muscle & heart, ultimately mobilizing fat into oxidative tissues for burning. Insulin induces hepatic ANGPTL3/8 secretion and glucagon suppresses it. This is why Reta, via the glucagon agonism, pulls on this system. What LPL does: It hydrolyzes (breaks down) stored triglycerides inside chylomicrons and VLDL particles. It releases free fatty acids that are taken up by the underlying tissue. When LPL is freed (ANGPTL3/8 low): triglyceride rich lipoproteins clear faster, plasma triglycerides fall, and remnant processing accelerates.